Filing Details

Accession Number:
0000947871-21-000348
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-18 21:04:54
Reporting Period:
2021-03-16
Accepted Time:
2021-03-18 21:04:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1796280 Oric Pharmaceuticals Inc. ORIC () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1282930 L Carl Gordon C/O Orbimed Advisors Llc
601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-03-16 41,353 $27.72 2,486,082 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-03-17 18,790 $28.43 2,467,292 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-03-18 6,059 $28.03 2,461,233 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. These shares of the Issuer's common stock were sold in a block order at a price of $27.72 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VI, LP ("OPI VI").
  2. These shares of the Issuer's common stock are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
  3. Each of the Reporting Person, OrbiMed Advisors, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VI is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  4. These shares of the Issuer's common stock were sold in a block order at a price of $28.43 pursuant to a Rule 10b5-1 trading plan established by OPI VI.
  5. These shares of the Issuer's common stock were sold in a block order at a price of $28.03 pursuant to a Rule 10b5-1 trading plan established by OPI VI.